HIV Vaccine Polypeptide Targeting Conserved Internal Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccines are limited in their ability to provide protection against multiple virus strains due to high mutation rates and variability in surface proteins, often requiring frequent updates and failing to elicit a broad cytotoxic T cell response across different MHC alleles.
Innovation Solution
Development of a polypeptide comprising specific immunogenic sequences with high homology to HIV proteins, such as those from VPR, VIF, REV, and NEF proteins, which can elicit a cytotoxic T cell response and provide protection against a variety of HIV strains, including mutated forms, by binding to multiple MHC alleles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If current HIV vaccines target surface proteins to elicit immune response, then vaccine development is straightforward, but the vaccines fail to provide protection against multiple virus strains due to high mutation rates and variability
Solution Approach 1:
The patent extracts and targets conserved internal protein sequences (such as those from Vpr, Vif, Rev, and Nef proteins) that are essential for viral replication but highly conserved across different HIV strains. By focusing on these internal conserved regions rather than variable surface proteins, the vaccine can elicit a broad cytotoxic T cell response that protects against multiple virus strains including mutated forms.
Solution Approach 2:
The patent identifies and targets specific local regions within HIV proteins that possess high conservation and immunogenicity. These local sequences (such as epitopes from internal proteins) have distinct properties compared to the overall protein structure - they are both conserved across strains and capable of eliciting strong immune responses, making them ideal vaccine targets.
2Reliability
If vaccines are updated frequently to match new virus strains, then protection against current strains is maintained, but the complexity and cost of vaccine deployment increases
Solution Approach 1:
The patent develops a universal vaccine approach that targets conserved sequences present across all major HIV strains and variants. By focusing on essential internal proteins that must remain conserved for viral function, a single vaccine formulation can provide broad protection against multiple current and future strains, eliminating the need for frequent updates and simplifying deployment.
3Reliability
If vaccines target variable surface proteins, then strain-specific protection is achieved, but the cytotoxic T cell response is not broad enough to cover different MHC alleles and virus variants
Solution Approach 1:
The patent goes beyond targeting a single epitope and instead targets multiple conserved epitopes from different internal HIV proteins (Vpr, Vif, Rev, Nef). This multi-epitope approach ensures that at least some epitopes will be recognized by T cells across different MHC alleles and virus variants, creating a broader and more resilient immune response.
Data Source
AI summary
The present specification discloses an immunogenic composition comprising polypeptide, wherein each of the polypeptides has no more than 100 amino acids, which polypeptides comprises one or more sequences having at least 60% homology with any of SEQ ID 1-4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-4 that has the same length as the epitope, wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete HIV virus protein.